Production of hybridomas secreting monoclonal antibodies against the lympholine osteoclast activating factor.
AUTOR(ES)
Luben, R A
RESUMO
The human lympholine osteoclast activating factor (OAF) is thought to be involved in several bone-destroying diseases. The current studies were designed to produce monoclonal antibodies against OAF for use in the subsequent design of immunoassays for OAF in clinical samples. Spleen cells from mice immunized with purified human OAF were hybridized with mouse plasmacytoma cells in vitro to yield hybridomas. Several clones of these hybridomas secreted into the culture medium antibodies, which neutralized the biological activity of OAF at dilutions as high as 1:100,000 relative to the initial culture medium. These antibodies did not interfere with the activities of parathyroid hormone in the same systems. These results represent the first report of monoclonal antibodies against a human lympholine, and validate the concept that hybridoma production is a useful technique for developing antibodies against weak or scarce antigens.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=372124Documentos Relacionados
- Production of hybridomas secreting monoclonal antibodies to the human leukocyte interferons.
- Development of hybridomas secreting monoclonal antibodies to the chicken intestinal 1 alpha,25-dihydroxyvitamin D3 receptor.
- Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor.
- Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin.
- Production of Monoclonal Antibodies Directed against the Microsporidium Enterocytozoon bieneusi